APA
NVCR icon

American Portfolios Advisors’s NovoCure NVCR Stock Holding History

American Portfolios Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4.56K Sell
60
-3
-5% -$234 ﹤0.01% 2852
2022
Q2 		$4.38K Sell
63
-21
-25% -$1.58K ﹤0.01% 2879
2022
Q1 		$6.96K Buy
84
+4
+5% +$295 ﹤0.01% 2833
2021
Q4 		$6.01K Sell
80
-110
-58% -$11K ﹤0.01% 2828
2021
Q3 		$22.1K Buy
190
+7
+4% +$1.06K ﹤0.01% 2240
2021
Q2 		$40.6K Buy
183
+83
+83% +$16.1K ﹤0.01% 1837
2021
Q1 		$13.2K Hold
100
– – ﹤0.01% 2260
2020
Q4 		$17.3K Buy
100
+50
+100% +$6.84K ﹤0.01% 1881
2020
Q3 		$5.57K Sell
50
-1,158
-96% -$92.6K ﹤0.01% 2231
2020
Q2 		$71.6K Buy
1,208
+1,008
+504% +$66.3K ﹤0.01% 1155
2020
Q1 		$13.5K Buy
200
+100
+100% +$7.9K ﹤0.01% 1687
2019
Q4 		$8.43K Sell
100
-530
-84% -$42.8K ﹤0.01% 2069
2019
Q3 		$47.1K Buy
+630
New +$50.4K ﹤0.01% 1303

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Portfolios Advisors's NVCR Position: Q3 2022 in Review

American Portfolios Advisors reduced its NovoCure (NVCR) stake by 4.8% in Q3 2022, selling an estimated $234 and leaving 60 shares worth $4.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

American Portfolios Advisors first reported a position in NVCR in Q3 2019 and has held it in 13 quarters since. The position peaked at $71.6K in Q2 2020. 304 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

  • American Portfolios Advisors held 60 shares of NovoCure worth $4.56K as of Q3 2022.
  • American Portfolios Advisors sold 3 NovoCure shares in Q3 2022, an estimated $234.
  • NovoCure made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2852 holding.
  • American Portfolios Advisors first reported a position in NovoCure in Q3 2019 and has held it in 13 quarters since.
  • American Portfolios Advisors's NovoCure position peaked at $71.6K in Q2 2020.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.